Biosimilars Labelling Magazine 
Pharmaceutical Technology
JUNE 23, 2025
Alvotech has moved one step closer to entering the Eylea (aflibercept 2 mg) biosimilar market, after a European Medicines Agency (EMA) panel recommended approval of its copycat biologic. Go deeper with GlobalData Reports LOA and PTSR Model - Aflibercept Biosimilar in Age Related Macular. CucuMberStudio via Shutterstock.
Pharmaceutical Technology
JULY 7, 2025
The positive results from the KONFIDENT trial were further supported by findings from the real-world KONFIDENT-S open-label extension study. Ekterly has the potential to become the foundational treatment for HAE and our focus now is on delivering it to the people who need it.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 11, 2025
Go deeper with GlobalData Reports LOA and PTSR Model - Bevacizumab Biosimilar in Endometrial Cancer Reports LOA and PTSR Model - Iparomlimab + Tuvonralimab in Nasopharyngeal C. NPC is a rare type of cancer in which malignant cells are formed in the upper part of the throat behind the nose. Find out more Sign up for our daily news round-up!
Pharmaceutical Technology
JULY 7, 2025
Robert Barrie July 7, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The application comes hot on the heels of positive data for Akeega unveiled at this year’s American Society of Clinical Oncology (ASCO) conference.
pharmaphorum
JULY 7, 2025
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued clear guidance for incorporating RWE in regulatory submissions, labelling expansions, and post-market monitoring. Oncology On the forefront of healthcare change, turning innovative sc.
pharmaphorum
JULY 2, 2025
Her career kicked off at 18, when she landed a role at Check Point after successfully cracking a series of online cybersecurity challenges the company had labelled as nearly unsolvable. Image Siwar El Assad 2 July, 2025 AI in pharma Bookmark this Market Access Balancing efficiency with risks: How biopharma companies can.
pharmaphorum
JULY 7, 2025
With its new filing, J&J seems to have set aside concerns about activity in non-BRCA patients, submitting Akeega for approval with a broad HRR-positive label claim. Competition from other PARP inhibitors in mCSPC could be on the way, though. Oncology In pursuit of a cure for cancer: An ASCO 2025 discussion wit.
Expert insights. Personalized for you.
52 
Let's personalize your content